Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)
Shanghai, CN
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.17% | -0.06% | -0.35% | -6.84% | -3.98% | -5.87% | -22.15% | -16.83% | -9.88% | +339.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 6 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+3.0% Q1'26: +6.4% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+25.2% ★ Q1'26: +5.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+0.2% ★ Q1'26: -2.2% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+3.0% Q1'26: +3.9% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+6.3% ★ Q1'26: +7.9% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×4.73× ★ Q1'26: 4.61× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 10 Rev. Ana. 10 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
105.52B
est: 106.58B (-1.0%)
|
120.76B
est: 121.26B (-0.4%)
|
130.85B
est: 133.21B (-1.8%)
|
159.08B
est: 157.97B (+0.7%)
|
186.57B
est: 186.71B (-0.1%)
|
191.91B
est: 196.18B (-2.2%)
|
215.82B
est: 218.31B (-1.1%)
|
231.98B
est: 237.58B (-2.4%)
|
260.30B
est: 267.12B (-2.6%)
|
275.25B
est: 279.97B (-1.7%)
|
283.58B
est: 286.10B (-0.9%)
|
297.09B
289.09B – 301.77B
+3.8% YoY
|
314.33B
297.99B – 323.91B
+5.8% YoY
|
337.12B
332.57B – 341.67B
+7.2% YoY
|
| EBITDA |
4.33B
est: 4.37B (-0.9%)
|
4.50B
est: 4.97B (-9.6%)
|
5.57B
est: 5.47B (+1.9%)
|
6.62B
est: 6.48B (+2.1%)
|
8.45B
est: 7.66B (+10.4%)
|
8.78B
est: 8.05B (+9.1%)
|
8.97B
est: 8.96B (+0.2%)
|
9.69B
est: 9.75B (-0.6%)
|
10.08B
est: 10.48B (-3.8%)
|
10.27B
est: 10.99B (-6.5%)
|
10.45B
est: 11.23B (-6.9%)
|
11.66B
11.35B – 11.84B
+3.8% YoY
|
12.34B
11.70B – 12.71B
+5.8% YoY
|
13.23B
13.05B – 13.41B
+7.2% YoY
|
| EBIT |
3.66B
est: 3.68B (-0.4%)
|
3.82B
est: 4.18B (-8.7%)
|
4.79B
est: 4.60B (+4.3%)
|
5.45B
est: 5.45B (-0.1%)
|
7.12B
est: 6.44B (+10.6%)
|
7.28B
est: 6.77B (+7.6%)
|
7.47B
est: 7.53B (-0.9%)
|
8.16B
est: 8.20B (-0.4%)
|
8.58B
est: 8.78B (-2.3%)
|
8.75B
est: 9.20B (-4.9%)
|
8.46B
est: 9.41B (-10.0%)
|
9.77B
9.50B – 9.92B
+3.8% YoY
|
10.33B
9.80B – 10.65B
+5.8% YoY
|
11.08B
10.93B – 11.23B
+7.2% YoY
|
| Net Income |
2.88B
est: 3.96B (-27.4%)
|
3.20B
est: 4.43B (-27.8%)
|
3.52B
est: 4.78B (-26.3%)
|
3.88B
est: 5.50B (-29.5%)
|
4.08B
est: 5.57B (-26.7%)
|
4.50B
est: 5.78B (-22.3%)
|
5.09B
est: 6.79B (-25.0%)
|
5.62B
est: 5.76B (-2.5%)
|
3.77B
est: 4.10B (-8.1%)
|
4.55B
est: 4.82B (-5.6%)
|
5.72B
est: 5.81B (-1.5%)
|
5.29B
5.14B – 5.44B
-8.9% YoY
|
5.93B
4.83B – 6.18B
+12.1% YoY
|
6.10B
5.72B – 6.49B
+2.9% YoY
|
| SGA |
4.59B
est: 5.59B (-17.9%)
|
5.14B
est: 6.36B (-19.2%)
|
6.33B
est: 6.99B (-9.4%)
|
8.92B
est: 8.29B (+7.7%)
|
10.83B
est: 9.79B (+10.5%)
|
16.71B
est: 10.29B (+62.4%)
|
10.78B
est: 11.45B (-5.9%)
|
11.31B
est: 12.46B (-9.3%)
|
10.90B
est: 12.79B (-14.8%)
|
9.53B
est: 13.41B (-28.9%)
|
18.23B
est: 13.70B (+33.0%)
|
14.23B
13.85B – 14.45B
+3.8% YoY
|
15.05B
14.27B – 15.51B
+5.8% YoY
|
16.15B
15.93B – 16.36B
+7.2% YoY
|
| EPS |
1.07
est: 1.07 (+0.0%)
|
1.19
est: 1.20 (-0.4%)
|
1.31
est: 1.29 (+1.6%)
|
1.37
est: 1.49 (-7.8%)
|
1.44
est: 1.50 (-4.1%)
|
1.58
est: 1.56 (+1.2%)
|
1.79
est: 1.83 (-2.3%)
|
1.61
est: 1.55 (+3.5%)
|
1.02
est: 1.11 (-7.9%)
|
1.23
est: 1.31 (-6.1%)
|
1.54
est: 1.59 (-3.2%)
|
1.44
1.39 – 1.47
-9.7% YoY
|
1.53
1.30 – 1.67
+6.6% YoY
|
1.67
1.54 – 1.75
+8.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yongzhong Li | Executive President & Executive Director | 3M | male |
| Bo Shen | President & Executive Director | 3M | male |
| Ming Dong | Executive Director | — | male |
| Pui Kiu Wong | Joint Company Secretary | — | female |
| Qiuhua Yang | Executive Chairman | — | male |
| Shuai Shao | Vice President | — | female |
| Shunjiang Yu | Chief Medical Officer | — | — |
| Tao Zhong | Vice President, Board Secretary & Joint Company Secretary | — | male |
| Yadong Zhou | Vice President & Chief Financial Officer | — | female |
| Ying Ke | Director & General Manager of R&D Management Center | — | — |
| Yong Zhao | Employee Representative Director & VP | — | male |
| Linqiong Dong | Securities Affairs Representative | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 601607.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
